ZEALAND PHARMA A/S (22Z.DE) Stock Overview
Europe - FRA:22Z - DK0060257814 - Common Stock
22Z.DE Key Statistics, Chart & Performance
The current stock price of 22Z.DE is 62.32 EUR. In the past month the price increased by 5.81%.
22Z.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.49 | 346.25B | ||
| AMG.DE | AMGEN INC | 13.35 | 135.02B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 15.87 | 131.38B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.56 | 128.80B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 25.3 | 94.65B | ||
| ARGX.BR | ARGENX SE | 95.12 | 43.57B | ||
| 1AE.DE | ARGENX SE | 94.35 | 43.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.79B | ||
| IDP.DE | BIOGEN INC | 9.4 | 19.01B | ||
| 0QF.DE | MODERNA INC | N/A | 9.03B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.85B | ||
| 1EXEL.MI | EXELIXIS INC | 17.15 | 8.26B |
Related stock screener links
About 22Z.DE
Company Profile
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Company Info
ZEALAND PHARMA A/S
Sydmarken 11
Soeborg DK
Employees: 424
Phone: 4588773600
ZEALAND PHARMA A/S / 22Z.DE FAQ
What does ZEALAND PHARMA A/S do?
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
What is the stock price of ZEALAND PHARMA A/S today?
The current stock price of 22Z.DE is 62.32 EUR. The price increased by 0.16% in the last trading session.
Does 22Z stock pay dividends?
22Z.DE does not pay a dividend.
What is the ChartMill rating of ZEALAND PHARMA A/S stock?
22Z.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the employee count for 22Z stock?
ZEALAND PHARMA A/S (22Z.DE) currently has 424 employees.
Can you provide the market cap for ZEALAND PHARMA A/S?
ZEALAND PHARMA A/S (22Z.DE) has a market capitalization of 2.87B EUR. This makes 22Z.DE a Mid Cap stock.
22Z.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 22Z.DE.
22Z.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 22Z.DE. 22Z.DE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
22Z.DE Financial Highlights
Over the last trailing twelve months 22Z.DE reported a non-GAAP Earnings per Share(EPS) of 12.71. The EPS increased by 921.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 73.34% | ||
| ROA | 38.89% | ||
| ROE | 42.8% | ||
| Debt/Equity | 0.02 |
22Z.DE Forecast & Estimates
24 analysts have analysed 22Z.DE and the average price target is 109.28 EUR. This implies a price increase of 75.36% is expected in the next year compared to the current price of 62.32.
For the next year, analysts expect an EPS growth of 638.53% and a revenue growth 11614.8% for 22Z.DE